Building evidence-based treatment recommendations for advanced anal cancer: the time is now
Mené en France sur 69 patients atteints d'un carcinome épidermoïde de l'anus de stade métastatique ou récidivant localement et non résécable, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'une chimiothérapie à base de docétaxel, cisplatine et fluorouracile
Achieving high levels of evidence for rare cancers is challenging. Low incidence and the resultant paucity of interest from health-care stakeholders have historically been barriers to doing prospective studies in such tumour types. These factors certainly apply to advanced anal squamous cell carcinoma, for which controversy still exists around the optimal treatment for the minority of patients who progress after chemoradiotherapy and are not suitable for salvage surgery. According to international guidelines, combination chemotherapy with cisplatin and fluorouracil or carboplatin and paclitaxel should be considered.
The Lancet Oncology , commentaire, 2017